Mitochondrial dysfunction in Parkinson's disease.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic, cellular, and animal studies with no new clinical data
PubMed 27453777 · doi:10.1186/s40035-016-0060-6
What was done
This narrative review summarizes literature regarding genetic and environmental factors contributing to mitochondrial dysfunction in Parkinson's disease, with a focus on mitochondrial complex I inhibition and the role of the PINK1/parkin pathway in mitophagy across post-mortem tissue, cellular systems, and animal models.
What was found
The abstract reports no numerical data, sample sizes, or effect estimates. It qualitatively reports that mitochondrial complex I activity is decreased in Parkinson's disease brains and preclinical models, and outlines the mechanism where PINK1 activates parkin to ubiquitinate outer mitochondrial membrane proteins, mediating selective degradation of damaged mitochondria.
Why it matters
It highlights how diverse genetic and environmental etiologies converge on common pathways of mitochondrial failure and impaired organelle quality control in dopaminergic neurodegeneration.
Limits
As a narrative review, it lacks a systematic literature search, quantitative meta-analysis, and original human clinical data. Much of the mechanistic evidence relies on toxin and transgenic animal models.
Cited by
- supports MPTP is a mitochondrial-targeting contaminant of illicit intravenous drugs from the 1980s that causes Parkinson's disease.